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STAGE-SPECIFIC FIVE-YEAR SURVIVAL OUTCOMES IN WOMEN TREATED FOR 
EARLY STAGE BREAST CANCER IN IBADAN, NIGERIA
ABSTRACT
Background: The disparity between the overall survival of breast cancer between high-income countries (HICs) and low- and 
middle-income countries (LMICs) has been majorly attributed to the high rate of diagnosis of Early Stage Breast Cancer 
(ESBC) in HICs, with about three-quarters and one-fifth of the total breast cancer patients diagnosed with ESBC in HICs and 
LMICs respectively. The median 5-year survival rate of ESBC in HICs is 86% while it is about 72% in Sub-Saharan Africa.
Objectives: To determine stage-specific five-year survival outcomes in women treated for ESBC.
Methods: We conducted a longitudinal, cohort study to assess the treatment and outcome of ESBC in a Nigerian tertiary 
hospital. Patients diagnosed and treated for ESBC over 5 years were recruited and followed up for a minimum of 5 years after 
treatment. Clinicopathologic parameters, disease progression and known vital status, were retrieved. A 5% level of 
significance was used.
Results: 67(9.6%)patients of 694 new cases of breast cancer seen over the study duration was treated for ESBC, of 
whichsixty- three (63) were followed up over the specified follow-up period. The mean age was 43(10) years. Based on the 
American Joint Committee on Cancer staging, 9 patients were stage IA, 16 stage IB, 16 stage IIA and 26 stage IIB respectively. 
The overall 5-year survival was 77.8%.
Conclusion: The survival pattern of our cohort fairly compares with reports in HICs, despite the challenges faced in the 
multimodal treatment protocol received by our patients.
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reast cancer is the leading cause of cancer and 
[1]cancer-related deaths in females globally.
However, Sub-Saharan Africa accounts for 10% of B
all breast cancer-related deaths worldwide despite having 
a lower incidence rate when compared to High-Income 
[2,3]Countries (HICs).  In a multi-continental comparative 
study, Nigeria had the third highest mortality rate 
irrespective of the stage at diagnosis and availability of 
[4]treatment options.  HICs such as those in the Asian pacific 
have a higher overall survival rate of 79% when compared 
to that of Low and Middle-Income Countries (LMICs) in 
 [5]Sub-Saharan Africa with a 12% survival rate.
The huge difference between the overall survival rates in 
both regions has been majorly attributed to the high rate of 
diagnosis of Early Stage Breast Cancer (ESBC) in HICs 
when compared with that of LMICs, and cutting-edge 
standard of care. About three-quarters of patients in HICs 
with breast cancers are diagnosed with ESBC as opposed to 
one-fifth of the total breast cancer patients diagnosed with 
[4]ESBC in LMICs.  The median 5-year survival rate of ESBC 
in HICs is 86% while it is about 72% in Sub-Saharan 
[6,7]Africa.
This difference in survival rates of ESBC is due to a 
combination of factors such as the age at presentation, 
tumour biology and availability of treatment options in 
these countries. Sub-Saharan Africa has a high prevalence 
of premenopausal patients, a basal-like breast tumour with 
triple-negative biology which carries a worse prognosis 
when compared to predominantly postmenopausal 
[8,9]patients in HICs.
However, early diagnosis may not be the only major factor 
considered in breast cancer survival since there is evidence 
of lead-time bias in patients who had no intervention when 
diagnosed with ESBC (stage 0 and 1), and who experienced 
a 3 to 10- year lag time before developing late-stage breast 
[10]cancer.   Comparing stage for stage, there was an eighty-
four percent 3-year survival rate for ESBC when compared 
to a 3-year survival rate of 56% for late-stage breast cancer 
[11]in Africa.  In this study, we review the treatment and 
outcomes of Early Stage Breast Cancer in our hospital over 
a nine-year follow-up period.
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METHODOLOGY
Our investigation was a longitudinal, cohort study aiming 
to assess the treatment and outcome of early-stage breast 
cancer. It was done in the Department of Surgery, 
University College Hospital, Ibadan. Ethical approval was 
obtained from the Oyo State Ministry of Health before the 
commencement of the study. Patients diagnosed and 
treated for ESBC over a 5-year period from January 1, 2009, 
to December 31, 2013, were recruited and followed up till 
December 31, 2018 (minimum of 5 years after diagnosis 
and treatment). The age, parity, tumour stage at 
presentation, tumour biology, disease progression and last 
known vital status were retrieved.
Patients with complete data set with a clinic opathological 
diagnosis of ESBC were included in the study. Patients 
who were neither ESBC at time of presentation or 
diagnosis or patients whose data were not appropriately 
stored were excluded. The follow-up protocol was clinical 
and radiologic (plain chest radiograph, abdominopelvic 
ultrasound scan along with a bone scan every year for the 
first 5 years and then every two years after.
Anonymity was ensured by converting the names of 
patients to coded numbers. Data extraction was done 
under the supervision of co-investigators by trained 
residents in the Oncology unit of our centre. Descriptive 
analysis in terms of frequency, mean, median and mode 
was generated from the data extracted. It was statistically 
analyzed using SPSS 20. The analyzed data were 
interpreted using tables and charts. A 5% level of 
significance was used for all tests.
RESULTS
A total of 694 new cases of breast cancer were seen over the 
study duration, of which 67(9.6%)patients hada diagnosis 
of ESBC. Sixty- three (63) of the ESBC patients were 
followed up as stated over the specified follow-up period, 
with 4 patients lost to follow-up.
The ages of the patients ranged between 21 and 82 years, 
with a mean of 43(10) years. Forty-six (69%) were 
postmenopausal, and the majority of them (84%) were 
multiparous. Based on the American Joint Committee on 
Cancer (AJCC) staging, nine (9) patients were stage IA, 16 
stage IB, 16 stage IIA and 26 stages IIB respectively.
The tumours were graded with the modified Scarff-Bloom-
Richardson system into a low, intermediate and high grade 
(figure 1). Thirty-nine patients (58%) had ER+ cancers, and 
19 (28%) had HER2-enriched tumours, of whom 11 
patients had immunotherapy with Herceptin®. About a 
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Figure 2:  Outcome of patients (n=63) 
Characteristics Median  n 
Median survival time (months)    47 (53)   63  
Local Recurrence   0 
Metastasis        13 
Visceral (lung, liver, Ovaries, Peritoneum)7 
Bone            13 
Brain 3 
Vital Status 
Alive with disease           5 
Alive without disease 44 
Dead from disease            12 
Dead from other causes 2 
Lost to follow up 4  
Figure 3: Kaplan-Meier Survival analysis by AJCC breast cancer stages over the follow up period.
155
Nigerian Journal of Medicine, Vol. 29 No. 1 January - March 2020 ISSBN 1115-2613
Figure 2.
Out of the 63 patients who were followed up for at least 5 
years, 49 were alive, 12 died from breast cancer, and 2 
patients died from causes other than breast cancer; the 
overall 5-year survival rate being 77.8%. The median 
survival time was 47(53) months (figure 2), with survival 
duration ranging from 3 to 90 months at the end of the 
follow-up period. All the four patients who were lost to 
follow-up had Stage IIB disease, defaulted from the out-
patient clinic and could no longer be reached within a year 
after diagnosis (3 – 11 months). All the 12 patients whose 
deaths were attributable to the disease died within 42 
months (11 – 42 months), and all had Stage 2 disease (1 – 
IIA, 11 – IIB). All seven patients who had surgery alone had 
clinical and radiological evidence of disease progression 
within 60 months; while all surviving patients with 
evidence of disease have histologically high-grade 
tumours.
None of the patients had local recurrence. Thirteen (13) 
patients had evidence of metastasis, the commonest site 
being the bone.  
Figure 3.
DISCUSSION
Demographic parameters that are often implicated in the 
poor outcome of breast cancer in LMICs are well 
[ 8 , 9 , 1 2 ]documented, including late presentation,  
[ 4 , 8 , 9 , 1 2 , 1 5 ]premenopausal status, younger age at 
[8,9] [4,8,9,12]diagnosis, unfavourabletumour biology  as well as 
[8]poor treatment compliance. .
In this study, 69% of the women were postmenopausal. 
This is in contrast to findings from other local studies 
conducted about a decade earlier, in which the majority of 
 patients were premenopausal. Huoet al reported 43.5%,
[13] [8] [12]Adesunkanmiet al 33.3%  and Ogundiranet al 42.4%  
postmenopausal patients respectively. It should, however, 
be noted that this study is limited to ESBC,unlike the other 
reports that recruited all stages of invasive breast cancer. 
Considering the fact that the mean age at diagnosis is 
surprisingly higher (49(10)) than previous reports, 
[13] [8] [12]
(46.8(11.3),  48(23-85), 47.4(11.4) ) and the fact that age 
at natural menopause in breast cancer patients previously 
[13]known to be 48.2(5.7);  consequently the possibility of a 
changing pattern in menopausal age should, therefore, be 
considered, even though our data may be too small and 
unpowered for such detection. This is important as the age 
range of our patients (21 – 82 years) is comparable to 
findings from other studies. In addition, the overwhelming 
majority of patients in the series reported by Ogundiranet 
al. were Stages I and II breast cancer cases, as they also 
reviewed only patients who had a mastectomy. One 
would, therefore, not have expected much disparity in the 
clinico-epidemiologic parameters, more so, 5-year survival 
status with respect to menopausal status was statistically 
significant (p<0.05). This trend is akin to the 
epidemiological picture in the western world – with the 
outlook that suggests that the epidemiological profile of 
our elderly breast cancer cohort is starting to mirror the 
western climes.
Majority of our patients (84%) were multiparous, which is 
 [8, 12]consistent with findings from other local studies,  thus 
supporting the finding that multiparity is protective of 
 [13]breast cancer, regardless of clinical stage.  However, 
considering the complexity of the relationship between 
parity, fertility and breast cancer, other factors such as the 
number of full-term pregnancies, breastfeeding, age at first 
birth and usage of hormonal contraceptives would have to 
be considered. The Nigerian Breast Cancer Study 
concluded that multiple live births, late menarche and 
extended breastfeeding are protective of breast cancer in 
Nigerian women, even though the overall trend is that of 
[16]increased breast cancer risk and incidence . The fact that 
women attain menarche at a younger age, deliberately give 
birth to fewer children and breastfeed for a shorter 
duration appears to obviate the positive impacts of the 
protective factors. In our series, parity had no statistical 
significance in determining long term survival.
Majority of the patients in this review had intermediate or 
high-grade tumours, which is in line with findings in the 
[8,9,14]literature.  With tumour grade a known independent 
predictor of patient outcome in breast cancer regardless of 
how early diagnosis is made, it is not surprising that all the 
patients who are still alive with the disease have high-
grade tumours (p>0.05).
Out of 694 newly-diagnosed breast cancer patients seen in 
our centre over the 5-year study period, only 67 (9.6%) 
were ESBC, which is barely half of the figures reported in 
[8,17]Nigerian literature, which ranged from 19.4% to 25.2%.  
Considering the fact that our centre serves a 
predominantly urban population that is expected to be 
more enlightened than the average Nigerian about 
common breast cancer screening modalities – self-breast 
examination, cl inical  breast examination and 
[18]mammography. This figure is considered low. This could 
be because we only reviewed ESBC patients who had 
prompt treatment of the early disease and subsequent 
follow-up, not the total number of patients diagnosed with 
ESBC while the denominator (694) comprises all indexed 
new cases, regardless of treatment. Ukwenyaet al. reported 
a reduction of ESBC from 45.2% at diagnosis to 25.2% at 
[16]treatment,  this attrition being attributable to poor social 
acceptance of mastectomy and inability to afford orthodox 
treatment, making the patients seek alternatives, and then 
later re-present with advanced disease.
None of the patients in our series had AJCC Stage 0 disease, 
which encompasses a spectrum of conditions – Paget's 
disease of the breast, ductal carcinoma in-situ and lobular 
carcinoma in-situ. This could be attributed to the paucity of 
information about preclinical diagnosis through screening 
modalities, relative unavailability of mammogram 
facilities, thelow sensitivity of screening mammogram in 
younger women as well as high-cost implications of a 
screening test. Besides, only patients who underwent 
treatment following diagnosis had their records indexed 
and entered into the breast cancer database, which 
probably excluded pre-invasive lesions.
About 58% of the tumours were ER+, which is in keeping 
[14]with 65% earlier reported.  With over 92% of the ER+ 
patients treated with hormonal therapy as an adjunct, we 
found a 100% 5-year survival and only 3 patients had 
evidence of disease progression within 5 years. Our 5-year 
survival outcomes were better in ER/PR+ tumours 
compared to triple-negative cancers (p<0.05). This further 
underscores the need for increased advocacy for hormonal 
manipulation of breast cancer in our population when 
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indicated by positive immunohistochemistry. Uptake of 
immunotherapy was, however not as satisfactory, as only 
11 out of 19 patients with HER-2 enriched tumours having 
immunotherapy. Treatment with trastuzumab, even 
though adjudged cost-effective, is also cost-intensive and 
many of the patients could not afford it. Only 22.8% of the 
patients referred to the Radiotherapy department were 
known to have received EBRT. The recurrent breakdown 
of the radiotherapy machine in our centre during the time 
of treatment coupled with consequent unbearable patient 
load in neighbouring tertiary centres with Radiotherapy 
units could be responsible for this. 
Most of the patients had a multimodal treatment plan, 
surgery being the mainstay. Breast cancer surgery was 
combined with one or more of immunotherapy, 
radiotherapy, chemotherapy and hormonal therapy. All 
the 7 patients who had surgery alone developed disease 
progression within 36 to 60 months. This further 
emphasizes the need for adjunct treatment options in 
combination with surgery in ESBC treatment.
The overall 5-year survival rate was 77.8% in this study, 
which is comparable to 86% reported for HICs and 72% for 
[6, 7]sub-Saharan Africa.  This review, being a single tertiary 
centre-based investigation has a tendency to inflate 
survival statistics since it was conducted in a leading 
Oncology centre in the sub-region with facilities and 
manpower for integrated cancer management, whereas 
[6]the CONCORD study  assessed a much larger dataset 
extracted from a national cancer registry in Algeria. In 
addition, the quoted 72% was for 5-year metastasis-free 
survival of EBSC (in Ethiopia). Nonetheless, the attention 
of researchers is being drawn to possible changing 
narratives in some LMICs as the survival of ESBC cases 
appear to be on the upward trend due to improvement in 
the standard of diagnostic modalities and cancer care.
The average survival time of patients in our series was 
47(53) months, compared to an estimated 9.5 to 30 months' 
average lifespan of a diagnosed breast cancer patient in 
[17]Nigeria . The estimate was generated from the dataset 
that includes all stages of breast cancer, such that early 
mortality in advanced breast cancer could have swung the 
average survival towards the unfavourable side.
The survival plots for Stages IA and IIA were similar 
(figure 3); however, there is a statistically significant 
difference in the survival outcome of the different group, 
with Stage IIB disease having the worst proportion of 
survival (p<0.05).
In conclusion, when compared stage-for-stage with breast 
cancer patients in HICs, the survival outcome of patients 
treated for ESBC in our cohort is not an abysmal tale of 
mortality, as our 5-year survival of 77.8% is not far behind 
86% reported in HICs. Considering the challenges faced in 
achieving optimal multimodal treatment protocol received 
by our patients, including poor uptake of immunotherapy 
and suboptimal access to radiation therapy, we project that 
survival pattern in our series could have competed fairly 
with that of HICs if treatment adjuncts were received as 
ideal.
Almost all the mortality recorded had stage IIB disease 
(92%), with the overall survival analysis significantly 
skewed by the IIB subset. This adds further credence to the 
growing debate whether IIB disease should be categorized 
as ESBC at all or if it should be adjudged to have clinical 
outcomes as stage III, especially since the common 
denominator is loco-regional disease spread, according to 
the SEER classification (Surveillance, Epidemiology and 
End Results), which found the 5-year relative survival of 
[19]regional breast cancer cases to be 85%.  Results of further 
research in our geographic location will elucidate more on 
this on a global perspective. 
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